Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$9.27 USD
+0.67 (7.79%)
Updated May 15, 2024 04:00 PM ET
After-Market: $9.28 +0.01 (0.11%) 6:36 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Sana Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 293 | 273 | 357 | 286 | 141 |
Income After Depreciation & Amortization | -293 | -273 | -357 | -286 | -141 |
Non-Operating Income | 10 | 3 | 1 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -283 | -269 | -356 | -285 | -138 |
Income Taxes | 0 | 0 | 0 | 0 | -8 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -283 | -269 | -356 | -285 | -131 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -283 | -269 | -356 | -285 | -131 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -269 | -257 | -346 | -280 | -139 |
Depreciation & Amortization (Cash Flow) | 25 | 16 | 11 | 6 | 2 |
Income After Depreciation & Amortization | -293 | -273 | -357 | -286 | -141 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 194.54 | 188.34 | 166.43 | 13.01 | NA |
Diluted EPS Before Non-Recurring Items | -1.63 | -1.81 | -1.79 | -11.56 | NA |
Diluted Net EPS (GAAP) | -1.46 | -1.43 | -2.14 | -21.92 | NA |
Fiscal Year end for Sana Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 110.73 | 90.62 | 2.18 | 116.29 | 84.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | -110.73 | -90.62 | -2.18 | -116.29 | -84.06 |
Non-Operating Income | 3.25 | 2.50 | 3.17 | 2.29 | 1.93 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -107.48 | -88.12 | 0.98 | -114.00 | -82.12 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -107.48 | -88.12 | 0.98 | -114.00 | -82.12 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -107.48 | -88.12 | 0.98 | -114.00 | -82.12 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 219.19 | 197.32 | 200.47 | 192.54 | 191.23 |
Diluted EPS Before Non-Recurring Items | -0.32 | -0.35 | -0.41 | -0.45 | -0.43 |
Diluted Net EPS (GAAP) | -0.49 | -0.44 | 0.00 | -0.59 | -0.43 |